Ketamine vs Psychedelics: Treatment Comparison Guide

If you've been searching for treatments beyond traditional antidepressants, you've probably encountered ketamine, psilocybin, and MDMA. All three show real promise for conditions that haven't responded to standard care. If you've been through the cycle of trying medications that don't work, that promise means something.

But the practical questions are harder to sort through. An estimated 30% of people with depression don't respond adequately to traditional antidepressants, and if you're among them, you need clear answers: Which of these can you actually access? What will it cost? And which one fits your situation?

The bottom line: Ketamine is the only psychedelic-adjacent treatment with broad, nationwide medical access right now. Esketamine (Spravato) is FDA-approved for treatment-resistant depression and available in all 50 states with insurance coverage. Psilocybin shows promise but is legal for supervised therapeutic use in only three states with no insurance coverage. MDMA was rejected by the FDA in 2024 and remains unavailable outside clinical trials.

Below is what each treatment actually offers and what that means for your decision.

Is Ketamine a Psychedelic?

Not exactly. Ketamine is classified as a dissociative anesthetic with psychedelic-like properties, not a classic psychedelic. The distinction matters because it directly affects what you can access and how each treatment feels.

Classic psychedelics like psilocybin and LSD primarily activate serotonin receptors and produce consciousness-expanding experiences that typically last 6–8 hours. MDMA works differently still. It's an empathogen that creates feelings of emotional openness and trust, which is why it's studied specifically for trauma. Ketamine blocks a different set of receptors entirely (N-methyl-D-aspartate, or NMDA, receptors) and produces a shorter dissociative experience, typically 45–70 minutes, with its own distinct antidepressant mechanism.

What they share is the ability to promote neuroplasticity, helping your brain form new connections through different pathways. That shared mechanism is why all three are studied for mental health conditions.

Ketamine Therapy

Ketamine works fundamentally differently from traditional antidepressants. Where selective serotonin reuptake inhibitors (SSRIs) require 4–8 weeks to take effect, ketamine can produce observable changes within 24 hours, with many people noticing improvement within hours to days. If you've spent months waiting for a medication to kick in, that speed matters. Esketamine (sold as Spravato) earned FDA approval specifically for treatment-resistant depression: cases where at least two antidepressants haven't worked.

How it works: ketamine blocks NMDA receptors, releasing a surge of glutamate, your brain's primary activation signal. That surge triggers production of brain-derived neurotrophic factor (BDNF), essentially fertilizer for brain cells. Preclinical and clinical evidence suggests ketamine rapidly increases synaptic connectivity in mood-related brain regions, potentially reversing stress-related neural damage over time.

The tradeoff is duration. In one frequently cited study of treatment-resistant depression patients, a single ketamine dose produced effects lasting about 13.2 days on average, and only 27% of patients maintained response at four weeks. That short duration is why ketamine treatment involves repeated sessions. A typical protocol includes an acute phase of 6–8 infusions over 2–4 weeks for IV, or weekly dosing for several weeks in at-home protocols, followed by individualized maintenance.

What the experience feels like: Most people describe a floating, dreamlike dissociation lasting under an hour. You remain conscious but detached from your usual thought patterns. Some find it deeply relaxing; others find it disorienting at first. People often describe feeling lighter in the days afterward, not euphoric, but as if the weight of depression has eased enough to engage with life again.

Psilocybin Therapy

Psilocybin works through the brain's serotonin system, activating receptors that reduce rigid thought patterns and promote cognitive flexibility. That mental loosening can break the cycles depression locks you into. Unlike ketamine's hours-to-days onset, psilocybin's therapeutic effects emerge over days to weeks and may persist far longer, a key differentiator explored in the comparison sections below.

What the experience feels like: Psilocybin sessions last 6–8 hours and can include vivid perceptual changes, emotional intensity, and what researchers call "mystical-type" experiences: feelings of interconnectedness or profound meaning. Sessions take place in a supervised clinical setting with trained facilitators present throughout.

Psilocybin has no FDA approval and remains federally illegal. Legal access for supervised therapeutic use is limited to Oregon, Colorado, and New Mexico.

MDMA-Assisted Therapy

MDMA creates a state of emotional openness by triggering a surge of serotonin and oxytocin. People can then process traumatic memories without the usual fear response. If you've avoided confronting certain experiences because the emotional weight feels unbearable, this mechanism makes MDMA-assisted therapy distinct from talk therapy alone. Research focuses specifically on severe post-traumatic stress disorder (PTSD), where it has the strongest evidence of any psychedelic-adjacent treatment, though the FDA rejected approval in 2024 and it remains unavailable outside clinical trials.

What the experience feels like: MDMA sessions last 6–8 hours and produce feelings of emotional warmth, trust, and reduced defensiveness. Unlike psilocybin, MDMA doesn't typically cause perceptual distortions. You remain clear-headed but emotionally open, which is why it pairs specifically with trauma processing.

How Do They Compare?

These figures come from different studies with different populations, designs, and outcome measures, so they should be treated as rough guides rather than definitive rankings.

Accessibility

Ketamine is the most broadly accessible of the three. You can access ketamine therapy through specialized clinics, certified providers, or telehealth programs across the country. As of early 2026, Drug Enforcement Administration (DEA) telemedicine flexibilities for controlled substances including ketamine have been extended, though timelines and requirements may change with future rulemaking.

Psilocybin facilities remain limited even in the three states where it's legal, with wait times and geographic constraints that make access difficult in practice. MDMA is restricted to clinical trials with limited enrollment.

Cost

Per-session pricing only tells part of the story. Here's what a full treatment course actually costs.

A typical ketamine protocol runs multiple sessions over several weeks. With Spravato and the manufacturer savings program, sessions can cost as little as $10 each. Medicare covers 80% of Spravato costs after you meet your deductible. IV ketamine without insurance runs $400–$1,000 per session, putting a full course at $2,400–$8,000. At-home programs with insurance coverage bring a full course to roughly $430–$600, while self-pay ranges from $660–$1,000.

For psilocybin, one or two sessions at $2,000–$3,500 each means $2,000–$7,000 entirely out of pocket. The per-session cost is much higher, but fewer sessions may be needed. MDMA therapy, if approved, would likely involve a high-cost multi-session course given the protocol's length and intensity, but no official pricing exists.

Ketamine vs Psilocybin for Depression

Both show meaningful efficacy for treatment-resistant depression, but through different profiles. IV ketamine produces the strongest immediate effect, with meta-analyses showing a large effect size. But effects often diminish over one to two weeks, with many patients losing response within the first week. Psilocybin demonstrates comparable antidepressant effects with benefits sustained for six or more months from one or two sessions in published trials, on the order of ten-plus times longer per dose. These figures come from separate studies with different designs, so direct comparison has real limits.

The practical question: would you rather start ongoing ketamine sessions now with insurance coverage, or pursue psilocybin access that may require fewer sessions but currently costs $2,000+ out of pocket in three states?

Ketamine vs MDMA for PTSD

MDMA has the strongest PTSD-specific evidence, with completed Phase 3 trials showing 71% of participants no longer meeting PTSD diagnostic criteria after 18 weeks (versus 48% with placebo). But the FDA's 2024 rejection cited trial blinding problems, safety monitoring concerns, and questions about real-world implementation. MDMA remains inaccessible outside research settings. Ketamine research for PTSD is in earlier stages, with emerging evidence from small trials suggesting benefit when paired with trauma-focused therapy like prolonged exposure.

The realistic choice today: ketamine therapy (available now) or enrolling in a clinical trial for MDMA (limited slots, uncertain timeline).

Safety and Side Effects

Each treatment carries distinct safety considerations, and understanding them is part of making an informed choice.

Ketamine side effects during sessions include dissociation, nausea, dizziness, and temporary blood pressure elevation. Long-term, high-frequency use carries a risk of urinary tract issues, though this is primarily associated with recreational misuse at much higher doses than therapeutic protocols. Ketamine also carries some dependence potential, which is why structured medical oversight matters. People with uncontrolled hypertension, a history of psychosis, or active substance use disorder are generally not good candidates.

Psilocybin side effects include nausea, headache, and anxiety during sessions. The more significant risk is psychological: "challenging experiences" can include intense fear, confusion, or paranoia, which is why supervised clinical settings with trained facilitators are essential. Psilocybin has very low physiological toxicity and minimal dependence potential.

MDMA carries cardiovascular risks (elevated heart rate and blood pressure), potential serotonin-related complications (especially dangerous if combined with SSRIs or other serotonergic drugs), and a risk of neurotoxicity at high or repeated doses. MDMA's dependence potential is moderate. These safety concerns were part of the FDA's reasoning for rejecting approval despite positive efficacy data.

Which Treatment Might Work for You?

If you have treatment-resistant depression and need relief soon, ketamine is the clearest path. It's the only option with FDA approval (as esketamine), nationwide access, and insurance coverage. Effects last one to two weeks per dose, so treatment involves ongoing sessions. But if you've spent months waiting for medications that never kicked in, ketamine's speed is the point.

If sustained benefit from fewer sessions matters more than immediate access, psilocybin's profile may appeal to you, but only if you live in Oregon, Colorado, or New Mexico and can pay $2,000–$3,500+ out of pocket. If you don't live in those states, this isn't a realistic option yet.

If you have severe PTSD, MDMA showed the strongest results in trials, but it's not available. Ketamine with trauma-focused therapy is the accessible alternative right now. If you're able to enroll in a clinical trial, that may also be worth exploring.

If cost is the deciding factor, ketamine with insurance is significantly more affordable than any other option on this list. A full at-home ketamine course can cost less than a single psilocybin session.

How Innerwell's At-Home Ketamine Therapy Works

If you've read this far and ketamine sounds like it could help, the next question is how to access it in a way that gives you the best chance at lasting improvement.

Research across all three of these treatments points to the same finding: medication creates a window of neuroplasticity, but therapeutic work determines whether benefits last. The medication opens a door. Therapy helps you walk through it. Integration sessions give you structured space to process what comes up during treatment and translate insights into lasting change. Without that support, effects tend to fade faster.

Innerwell builds this therapeutic structure into every step. Licensed psychotherapists, Master's and Doctoral level clinicians rather than unlicensed guides, provide preparation before sessions and integration therapy afterward. The result is comprehensive mental health treatment that uses ketamine as one tool within a structured therapeutic framework, not medication delivery with minimal oversight.

The process:

1. Evaluation: A psychiatric clinician conducts your initial assessment, reviewing your diagnosis, past treatment responses, current medications, and screening for contraindications. Not everyone is a good candidate, and that honesty is part of what makes the process trustworthy.
2. Delivery: Sublingual ketamine tablets ship directly to your home. During the acute treatment phase, you'll typically take ketamine once weekly.
3. Preparation and integration: Licensed psychotherapists provide structured support before and after each session to translate ketamine's neuroplasticity window into lasting change.
4. Ongoing monitoring: Your psychiatric clinician tracks your progress throughout treatment and adjusts the approach based on your response.

Cost

Innerwell accepts insurance in select states. With coverage, sessions run $54–$75 per treatment. Self-pay patients pay $83–$125 per session. A full 8-session Foundation course costs $599 with insurance or $998 self-pay.

Clinical Outcomes

Innerwell patients report a 69% reduction in depression symptoms and 60% reduction in anxiety symptoms after 10 weeks. 87% see improvement within four weeks, with an average patient rating of 4.7 out of 5.

Take the free assessment to see if ketamine therapy might work for you.

Frequently Asked Questions

Is ketamine better than psilocybin for depression?

They work through different profiles, and which is "better" depends on your situation. Ketamine acts faster but requires repeated sessions. Psilocybin may produce longer-lasting effects from fewer sessions but lacks FDA approval and costs significantly more. The practical advantage of ketamine is that you can access it now, with insurance, in all 50 states.

Can I get psilocybin or MDMA therapy legally today?

Psilocybin is legal for supervised therapeutic use in Oregon, Colorado, and New Mexico, though sessions cost $2,000–$3,500+ out of pocket with limited facility availability. MDMA is not legally available outside clinical trials. Ketamine remains the only psychedelic-adjacent therapy with nationwide access and insurance coverage.

Can I use my HSA or FSA for ketamine therapy?

HSA and FSA funds can often cover ketamine therapy costs when treatment is prescribed for a diagnosed condition and accepted as medically necessary by your plan administrator. This includes co-pays for Spravato, IV infusion sessions, and at-home programs like Innerwell.

How long do I need to stay on ketamine therapy?

Initial protocols typically run 8–12 weeks. Because ketamine's effects fade without continued treatment, many people transition to maintenance protocols with less frequent dosing.

What if ketamine doesn't work for me?

About 30–50% of people don't respond adequately to ketamine. Options include adjusting your protocol (different dosing or more sessions), adding therapeutic approaches like cognitive behavioral therapy (CBT) or prolonged exposure, trying a different delivery method, or working with a comprehensive provider who can evaluate your full treatment picture.